Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ANTX
$1.02
$
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Next Earnings
2026-02-25
Beta
-0.032
Average Volume
Market Cap
Last Dividend
CIK
0001880438
ISIN
US0373261058
CUSIP
037326105
CEO
Eric E. Easom
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
22
IPO Date
2022-03-25
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference | MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026 at 3:40 PM ET. A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived. | Business Wire | 2026-02-17 07:00:00 |
| AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease | MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the U.S. Food and Drug Administration has cleared Oregon Health & Science University's (OHSU) Investigational New Drug (IND) application to proceed with an IIT that will evaluate the safety, efficacy, and pharmacokinetics of epetraborole in patients with Mycobacterium abscessus lung. | Business Wire | 2026-01-12 07:00:00 |
| AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock? | AN2 Therapeutics (ANTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). | Zacks Investment Research | 2026-01-09 13:00:54 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| SC 13G | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| 3 | 2026-02-03 | 2026-02-03 | View Filing |
| 8-K | 2026-01-29 | 2026-01-29 | View Filing |
| 4 | 2026-01-14 | 2026-01-14 | View Filing |
| 4 | 2026-01-14 | 2026-01-14 | View Filing |
| 4 | 2026-01-14 | 2026-01-14 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| SC 13G | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 4 | 2025-11-06 | 2025-11-06 | View Filing |
| 4 | 2025-11-06 | 2025-11-06 | View Filing |
| 4 | 2025-10-14 | 2025-10-14 | View Filing |
| 4 | 2025-10-14 | 2025-10-14 | View Filing |
| 4 | 2025-10-14 | 2025-10-14 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| 4 | 2025-07-11 | 2025-07-11 | View Filing |
| 4 | 2025-07-11 | 2025-07-11 | View Filing |
| 4 | 2025-07-11 | 2025-07-11 | View Filing |
| 8-K | 2025-06-20 | 2025-06-20 | View Filing |
| SC 13D/A | 2025-06-18 | 2025-06-18 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 8-K | 2025-06-11 | 2025-06-11 | View Filing |
| SC 13G | 2025-06-04 | 2025-06-04 | View Filing |
| 4 | 2025-06-03 | 2025-06-03 | View Filing |
| SC 13D/A | 2025-05-30 | 2025-05-30 | View Filing |
| 4 | 2025-05-30 | 2025-05-30 | View Filing |
| 4 | 2025-05-29 | 2025-05-29 | View Filing |
| 8-K | 2025-05-27 | 2025-05-27 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| SC 13D | 2025-05-07 | 2025-05-07 | View Filing |
| 8-K | 2025-05-01 | 2025-05-01 | View Filing |
| 4 | 2025-04-11 | 2025-04-11 | View Filing |
| 4 | 2025-04-11 | 2025-04-11 | View Filing |
| 4 | 2025-04-11 | 2025-04-11 | View Filing |
| ARS | 2025-04-11 | 2025-04-10 | View Filing |
| DEFA14A | 2025-04-10 | 2025-04-10 | View Filing |
| DEF 14A | 2025-04-10 | 2025-04-10 | View Filing |
| S-8 | 2025-03-25 | 2025-03-25 | View Filing |
| 10-K | 2025-03-25 | 2025-03-25 | View Filing |
| 8-K | 2025-03-25 | 2025-03-25 | View Filing |
| SC 13G/A | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-13 | 2025-02-13 | View Filing |
| SC 13G/A | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2024-12-23 | 2024-12-23 | View Filing |
| 4 | 2024-12-23 | 2024-12-23 | View Filing |
| 4 | 2024-12-23 | 2024-12-23 | View Filing |
| 4 | 2024-12-23 | 2024-12-23 | View Filing |
| 4 | 2024-12-23 | 2024-12-23 | View Filing |
| 4 | 2024-12-10 | 2024-12-10 | View Filing |
| 4 | 2024-11-27 | 2024-11-27 | View Filing |
| 4 | 2024-11-27 | 2024-11-27 | View Filing |
| 4 | 2024-11-21 | 2024-11-21 | View Filing |
| 4 | 2024-11-20 | 2024-11-20 | View Filing |
| 4 | 2024-11-18 | 2024-11-18 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-13 | 2024-11-13 | View Filing |
| 10-Q | 2024-11-13 | 2024-11-13 | View Filing |
| 8-K | 2024-11-13 | 2024-11-13 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Quantum Inspired Strategy | 31.74% | 1 | 283 | 0.04 | 0.08 | 36.82 |
| Keltner Channel Strategy | 27.87% | 1.04 | 93 | 0.04 | 0.11 | 32.95 |
| Williams PercentR Strategy | 27.71% | 1 | 238 | 0.04 | 0.07 | 32.79 |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | x | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | x | x | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |